Bifidobacterium lactis XLTG11 Alleviates Cyclophosphamide-induced Immunosuppression in Mice
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The effects of Bifidobacterium lactis XLTG11 on immune function utilizing an immunosuppressed mouse model that was constructed using cyclophosphamide (CTX) were investigated. The blank control and model groups were given normal saline, the positive control group was given levamisole hydrochloride (LEV) (10 mg/kg), and the experimental groups were given B. lactis XLTG11 at different concentrations (1×109, 1×108, 1×107, or 1×106 CFU) for 28 consecutive days; subsequently, immunological indices were measured. All mice dosed with B. lactis XLTG11 resisted CTX damage to the thymus; their thymic indices increased by 37.37%, 43.43%, 56.56%, and 84.84% (p<0.05), respectively, compared with those of the model group. Additionally, the experimental groups showed increases in plantar thickness of 38.24%, 50.00%, 55.89%, and 94.12% (p<0.05), respectively. Higher villus height and goblet cell number in the small intestines (p<0.05) were also observed, with those of the 1×109 CFU group increasing by 20.82% (p<0.01) and 51.23% (p<0.01), respectively. Moreover, elevated serum immunoglobulin and cytokine levels were detected (p<0.05). IgA, IL-2, and TNF-α levels increased the most; in the 1×109 CFU group, IgA increased by 20.03% (p<0.01), IL-2 by 35.94% (p<0.01), and TNF-α by 14.50% (p<0.05). Therefore, B. lactis XLTG11 enhanced the immune function of immunocompromised mice in a dose-dependent manner. Our findings can serve as a theoretical basis for the development and use of probiotic health foods.
